AYTU BIOPHARMA, INC (AYTU) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.04

From 52W high−26.90%

Volume54647.00

Market cap$22.75M

P/E (TTM)—

P/S (TTM)0.4x

Div yield—

Key dataSep 18, 2026

Open

$2.04

From 52W high

−26.90%

Volume

54647.00

Market cap

$22.75M

ValuationView details →

P/E (Fwd)

8.5x

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

40.6

MomentumView details →

1D Return

+6.00%

YTD Return

−20.77%

SummaryUpdated Mar 1, 2026

Aytu BioPharma, Inc. (NASDAQ:AYTU) is a specialty pharmaceutical company founded in 2015 and headquartered in Englewood, Colorado. Originally incorporated as Aytu BioScience, the company changed its name to Aytu BioPharma in March 2021. The company has undergone significant strategic transformation over recent years, evolving from a multi-segment operation with consumer health and clinical development programs into a focused specialty pharmaceutical company concentrating exclusively on commercializing prescription medications for ADHD and pediatric conditions.

Ask drillr about AYTU BIOPHARMA, INC →

ValuationView details →

P/E (Fwd)

8.5x

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

0.3x

P/S (TTM)

0.4x

P/B (TTM)

0.6x

ProfitabilityView details →

Gross Margin

62.50%

Net Margin

−60.17%

EBITDA Margin

−48.28%

ROE (TTM)

−96.90%

ROA (TTM)

−30.49%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

−18.24%

EPS YoY

—

FCF YoY

+127.09%

Revenue CAGR 3Y

−11.78%

EPS CAGR 3Y

+24.48%

EBITDA YoY

—

MomentumView details →

1D Return

+6.00%

YTD Return

−20.77%

1Y Return

−15.57%

RSI (14)

40.6

vs 50D SMA

−7.01%

vs 200D SMA

−13.54%

Capital & dividendView details →

Debt/Equity

0.65x

Current Ratio

1.12x

Quick Ratio

1.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

−70.97%

Beats (12Q)

3/12

Next Q EPS Est

−$0.01

Avg Surprise (4Q)

−402.04%

Rev Surprise

2.97%

Financials snapshotView financials →

Revenue (TTM)

56.60M

Net Income (TTM)

−34.05M

Op. CF (TTM)

1.68M

Next earningsSep 22, 2026 →

Latest newsMore news →

Aytu BioPharma announced it will report its fiscal 2026 full year and fourth quarter operational and financial results after market close on September 22, 2026, with a conference call and webcast the same day.4d ago

Similar companies

Universe Pharmaceuticals Inc.UPC TherapeuticsMD, Inc.TXMD Biofrontera Inc.BFRI Quantum BioPharma Ltd.QNTM Rockwell Medical, Inc.RMTI Cosmos Health Inc.COSM Find similar companies →

Latest newsMore news →